abrdn plc Acquires Shares of 232,900 Immatics (NASDAQ:IMTX)

abrdn plc acquired a new stake in shares of Immatics (NASDAQ:IMTX) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 232,900 shares of the company’s stock, valued at approximately $2,657,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Perceptive Advisors LLC grew its stake in shares of Immatics by 76.5% in the second quarter. Perceptive Advisors LLC now owns 8,086,159 shares of the company’s stock worth $93,961,000 after acquiring an additional 3,503,750 shares during the period. RA Capital Management L.P. bought a new stake in shares of Immatics in the first quarter worth approximately $18,392,000. Frazier Life Sciences Management L.P. bought a new stake in shares of Immatics in the second quarter worth approximately $13,392,000. Price T Rowe Associates Inc. MD grew its stake in shares of Immatics by 38.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,225,360 shares of the company’s stock worth $33,899,000 after acquiring an additional 891,191 shares during the period. Finally, Baker BROS. Advisors LP grew its stake in shares of Immatics by 10.4% in the first quarter. Baker BROS. Advisors LP now owns 6,443,398 shares of the company’s stock worth $67,720,000 after acquiring an additional 604,545 shares during the period. 64.41% of the stock is currently owned by institutional investors.

Immatics Trading Up 2.5 %

IMTX opened at $9.33 on Monday. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -10.48 and a beta of 0.78. The company’s 50 day moving average is $10.81 and its 200 day moving average is $11.35. Immatics has a 12-month low of $7.80 and a 12-month high of $13.77.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.17. The company had revenue of $20.19 million for the quarter, compared to the consensus estimate of $12.36 million. Immatics had a negative net margin of 103.99% and a negative return on equity of 23.34%. As a group, analysts predict that Immatics will post -0.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IMTX has been the subject of a number of research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immatics in a research note on Thursday, September 5th. Piper Sandler began coverage on shares of Immatics in a report on Monday, October 7th. They issued an “overweight” rating and a $19.00 price objective on the stock.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.